| Morphologically Altered Astrocytes | |
|---|---|
| Lineage | Glia > Astrocyte > Reactive/Alteration |
| Markers | GFAP, Vimentin, Nestin, S100B |
| Brain Regions | Cortex, Hippocampus, Substantia Nigra, Brain Parenchyma |
| Disease Association | Alzheimer's Disease, Parkinson's Disease, Epilepsy, Traumatic Brain Injury |
Morphologically Altered Astrocytes refer to astrocytes that have undergone significant changes in response to pathological insults, injury, or disease[1]. These alterations represent a spectrum of reactive changes that fundamentally transform astrocyte morphology, gene expression, and function. Once considered merely passive responders to neuronal injury, morphologically altered astrocytes are now recognized as active drivers of disease progression and potential therapeutic targets[2].
Morphologically Altered Astrocytes are astrocytes classified within the Glia > Astrocyte > Reactive lineage[1:1]. These cells are found throughout the Brain Parenchyma including the Cortex, Hippocampus, and Substantia Nigra. They are characterized by expression of marker genes including GFAP (Glial Fibrillary Acidic Protein), Vimentin, Nestin, and S100B. They are involved in Alzheimer's Disease, Parkinson's Disease, Epilepsy, and Traumatic Brain Injury.
The most characteristic morphological change in reactive astrocytes is cellular hypertrophy—a dramatic increase in cell body size and process thickness[3]:
Reactive astrocytes exhibit altered process dynamics:
Nuclear morphology also changes in morphologically altered astrocytes:
Morphologically altered astrocytes show increased expression of:
| Category | Genes | Function |
|---|---|---|
| Intermediate filaments | GFAP, Vimentin, Nestin | Cytoskeletal restructuring |
| Cytokines | IL-6, IL-1β, TNF-α | Inflammatory signaling |
| Chemokines | CCL2, CXCL10 | Immune cell recruitment |
| Growth factors | BDNF, GDNF, CNTF | Neurotrophic support |
| Complement proteins | C3, C4 | Synaptic elimination |
Normal astrocyte functions are often reduced:
Morphological alterations vary by brain region[4]:
Cortical astrocytes show laminar-specific responses:
Hippocampal astrocytes exhibit unique alterations:
Nigral astrocytes demonstrate:
In Alzheimer's disease, morphologically altered astrocytes contribute to[5]:
In Parkinson's disease, altered astrocytes[6]:
In Epilepsy, reactive astrocytes[7]:
Following TBI:
The discovery of distinct reactive astrocyte phenotypes has revolutionized understanding[2:1]:
Targeting morphologically altered astrocytes offers multiple therapeutic strategies[8]:
Study of Morphologically Altered Astrocytes employs various techniques:
Pekny M, Pekna M. Reactive gliosis in the pathogenesis of CNS diseases. Nat Rev Neurosci (2016). 2016. ↩︎ ↩︎
Liddelow SA et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature (2017). 2017. ↩︎ ↩︎
Sofroniew MV, Vinters HV. Astrocytes: Biology and pathology. Acta Neuropathol (2010). 2010. ↩︎
Zhang Y, Barres BA. Astrocyte heterogeneity: An underappreciated topic. J Neurochem (2010). 2010. ↩︎
Wilhelmsson U et al. Astrocytes in Alzheimer's disease. J Neuroinflammation (2022). 2022. ↩︎
Zhang Y et al. Molecular landscape of astrocyte in Parkinson's disease. Nat Neurosci (2019). 2019. ↩︎
Coulter DA, Steinhäuser C. Role of astrocytes in epilepsy. Cold Spring Harb Perspect Med (2015). 2015. ↩︎
Escartin C et al. Reactive astrocyte nomenclature. Nat Neurosci (2021). 2021. ↩︎